Summary
APLS Chart
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.38 per share. This compares to a loss of $0.74 per share a year ago.
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?
Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Apellis Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 4 | $90.67 | $90.67 | - | - |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 67 | $2.72 | $2.72 | - | - |
 Farallon Capital Farallon Capital Management LLC | 6,000 | $241,380 | $241,380 | - | - |
 George Soros Soros Fund Management LLC | 1.06M | $42.48M | $42.48M | - | - |
 Bridgewater Associates LP Bridgewater Associates LP | 34,913 | $877,014.66 | $877,014.66 | - | - |
Apellis Pharmaceuticals Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anupam Rama JP Morgan | 654.06 | $3,613.19 | $2,340.22 | -$1,272.97 | -35.23% |
 Eliana Merle Barclays | 1,045.37 | $24,992.78 | $3,740.33 | -$21,252.45 | -85.03% |
| JS Joseph Stringer Needham | 10,868.51 | $36,689.36 | $38,887.52 | $2,198.16 | 5.99% |
 Yigal Nochomovitz Citigroup | 142.05 | $485.03 | $508.24 | $23.21 | 4.79% |
Apellis Pharmaceuticals Inc. (APLS) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Apellis Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Cedric Francois CEO | NASDAQ (NGS) Exchange | 03753U106 CUSIP |
| US Country | 705 Employees | - Last Dividend | - Last Split | 9 Nov 2017 IPO Date |
Overview
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutic compounds. Founded in 2009 and based in Waltham, Massachusetts, Apellis focuses on leveraging the inhibition of the complement system to address autoimmune and inflammatory diseases. The company's approach involves targeting various aspects of the complement system, a part of the immune system that plays a critical role in inflammation and serves as a powerful mechanism for defending against pathogens. Through its deep understanding of the complement system, Apellis aims to develop innovative treatments that can provide significant benefits to patients with diseases that currently have limited therapeutic options.
Products and Services
-
EMPAVELI
Apellis offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), immune complex membranoproliferative glomerulonephritis (IC-MPGN), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA). EMPAVELI represents a significant advancement in the treatment of these severe and rare diseases by specifically targeting the complement system to control disease progression.
-
SYFOVRE
SYFOVRE is designed for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Geographic atrophy is a progressive disease of the retina that can lead to blindness, and SYFOVRE represents an important step forward in addressing the underlying causes of this condition by inhibiting specific components of the complement system.
-
APL-3007
In its commitment to innovation, Apellis is developing APL-3007, a small interfering RNA (siRNA), currently in a Phase 1 clinical trial. This potential therapeutic represents a novel approach to complement inhibition, utilizing RNA interference technology to potentially treat complement-mediated disorders.
-
Oral Complement Inhibitor
Further expanding its pipeline, Apellis is also working on an oral complement inhibitor. Currently in preclinical development, this product aims to offer a convenient, orally administrated treatment option for patients with complement-driven diseases, highlighting Apellis’ commitment to broadening accessibility and improving patient outcomes.
In addition to its proprietary developments, Apellis has strategic collaborations to augment its portfolio and enhance its research capabilities. Notably, it has entered into a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for the development and commercialization of pegcetacoplan. Moreover, a collaboration with Beam Therapeutics Inc. focuses on utilizing Beam's base editing technology for discovering new treatments for complement-driven diseases, underscoring Apellis' innovative approach in the biopharmaceutical field.
